Immunotherapy for prostate cancer

Dendritic cells and the control of immunity

1998 • 14,345 citations

Cancer Statistics, 2005

2005 • 5,487 citations

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2004 • 5,439 citations

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

2004 • 3,606 citations

Enhancement of Antitumor Immunity by CTLA-4 Blockade

1996 • 3,585 citations

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 • 2,828 citations

CTLA-4 can function as a negative regulator of T cell activation

1994 • 2,107 citations

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

1995 • 2,090 citations

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1996 • 1,908 citations

Prostate-specific membrane antigen expression in normal and malignant human tissues.

1997 • 1,454 citations

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

2006 • 1,069 citations

Homeostasis and Self-Tolerance in the Immune System: Turning Lymphocytes off

1998 • 989 citations

CTLA-4: new insights into its biological function and use in tumor immunotherapy

2002 • 923 citations

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.

1996 • 922 citations

Dendritic Cells in Cancer Immunotherapy

2000 • 698 citations

Clinical significance of defective dendritic cell differentiation in cancer.

2000 • 694 citations

General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes

1984 • 652 citations

The Emerging Role of CTLA-4 as an Immune Attenuator

1997 • 637 citations

Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells

2000 • 627 citations

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1996 • 613 citations

Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins.

2001 • 597 citations

Autoantibody Signatures in Prostate Cancer

2005 • 584 citations

Expression of the prostate-specific membrane antigen.

1994 • 582 citations

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1998 • 563 citations

A Kinetic Basis For T Cell Receptor Repertoire Selection during an Immune Response

1999 • 515 citations

Clinical use of Prostate Specific Antigen in Patients with Prostate Cancer

1989 • 511 citations

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

2002 • 491 citations

Phase I Trial of ¹⁷⁷Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

2005 • 486 citations

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

1999 • 468 citations

Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade

2005 • 465 citations

Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.

1999 • 452 citations

Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

1997 • 443 citations

Decreased antigen presentation by dendritic cells in patients with breast cancer.

1997 • 439 citations

Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.

2000 • 421 citations

Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

1998 • 419 citations

Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1993 • 411 citations

Vaccinia Virus: A Tool for Research and Vaccine Development

1991 • 410 citations

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1996 • 398 citations

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1997 • 383 citations

Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.

1996 • 380 citations

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

2001 • 373 citations

Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.

1996 • 360 citations

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

2000 • 355 citations

Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer

2005 • 352 citations

Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells

1994 • 319 citations

Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor

1998 • 316 citations

Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer

2004 • 310 citations

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

2000 • 300 citations

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

2005 • 279 citations

Hematologic effects of flt3 ligand in vivo in mice

1996 • 272 citations

Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.

1990 • 269 citations

In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen

1997 • 267 citations

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

2000 • 260 citations

Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy

2001 • 257 citations

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

2000 • 254 citations

Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes

2004 • 254 citations

Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man

1999 • 253 citations

Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group

2004 • 252 citations

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

1998 • 246 citations

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1999 • 242 citations

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancer

2002 • 230 citations

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy

1999 • 223 citations

Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation.

2001 • 215 citations

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.

1997 • 215 citations

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1999 • 206 citations

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

2001 • 198 citations

Prostate-specific antigen

1999 • 198 citations

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.

1997 • 197 citations

Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro

2000 • 194 citations

FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice

1997 • 193 citations

Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment

1999 • 191 citations

Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.

1995 • 190 citations

Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial

2004 • 187 citations

Naked DNA and Adenoviral Immunizations for Immunotherapy of Prostate Cancer: A Phase I/II Clinical Trial

2000 • 185 citations

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1995 • 185 citations

( ¹¹¹ ) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY

1998 • 177 citations

Intraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II Study

1997 • 177 citations

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1995 • 174 citations

Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial.

2000 • 164 citations

Follow-up evaluation of a phase II prostate cancer vaccine trial

1999 • 147 citations

Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.

2000 • 145 citations

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

1999 • 145 citations

Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.

1999 • 144 citations

Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.

1996 • 132 citations

Expression of the flt3 receptor and its ligand on hematopoietic cells.

1995 • 125 citations

Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.

1994 • 121 citations

Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model.

1997 • 117 citations

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1995 • 109 citations

Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase

1988 • 100 citations

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen

1997 • 99 citations

Dendritic cells: a major story unfolds

1995 • 97 citations

Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer

2002 • 97 citations

Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.

2002 • 96 citations

Anti‐tumor effects of toxins targeted to the prostate specific membrane antigen

2002 • 92 citations

Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses

1990 • 90 citations

Indium-111 Capromab Pendetide (ProstaScint) Imaging to Detect Recurrent and Metastatic Prostate Cancer

1998 • 88 citations

Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival

2001 • 87 citations

Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172)

1998 • 86 citations

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies

2000 • 78 citations

HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate Cancer

2001 • 75 citations

Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.

1999 • 72 citations

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8⁺ T cells in prostate cancer patients

2002 • 72 citations

A Phase II Trial of Humanized Anti‐Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen‐Independent Prostate Cancer

2001 • 70 citations

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

1999 • 69 citations

Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.

1998 • 67 citations

Dramatic Numerical Increase of Functionally Mature Dendritic Cells in FLT3 Ligand-Treated Mice

1997 • 66 citations

Androgen Suppression by Hydrocortisone without Aminoglutethimide in Orchiectomised Men with Prostatic Cancer

1987 • 58 citations

EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.

2003 • 54 citations

Tumor Associated Glycoprotein-72 is Highly Expressed in Prostatic Adenocarcinomas

1994 • 45 citations

Phase II Trial of GM-CSF in Advanced Prostate Cancer

2001 • 43 citations

A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC)

2004 • 43 citations

Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.

2000 • 36 citations

Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center.

1999 • 35 citations

Safety and Biological Activity of Repeated Doses of Recombinant Human Flt3 Ligand in Patients with Bone Scan-Negative Hormone-Refractory Prostate Cancer

2004 • 33 citations

Granulocyte-macrophage colony-stimulating factor protects dendritic cells from liposome-encapsulated dichloromethylene diphosphonate-induced apoptosis through a Bcl-2-mediated pathway

1999 • 32 citations

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

2002 • 32 citations

Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein

2004 • 30 citations

Radioimmunotherapy of prostate cancer.

2004 • 30 citations

Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

2005 • 30 citations

A phase II study of PROSTVAC-VF vaccine, and the role o f GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC)

2005 • 28 citations

Response criteria in prostatic carcinoma.

1999 • 20 citations

Inhibition of human immunodeficiency virus type 1 replication by human interferons alpha, beta and gamma.

1993 • 11 citations

PS1 Late breaking Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final progression and survival data from a second Phase 3 trial

2005 • 11 citations

Characterization of Anti‐Prostatic Acid Phosphatase Monoclonal Antibody and its Medical Significance

1988 • 10 citations

A Phase 2 Study of an Allogeneic GM-CSF Gene-Transduced Prostate Cancer Cell Line Vaccine in Patients with Metastatic Hormone-Refractory Prostate Cancer

2004 • 7 citations